For women with HER2-positive early breast cancer treated with an anthracycline-based regimen followed by trastuzumab (Herceptin), concurrent therapy with the angiotensin-converting enzyme (ACE) inhibitor lisinopril can help to prevent a decline in left-ventricular ejection fraction (LVEF) below 50%, investigators in a community-based study found. Among 424 women with HER2-positive early-stage breast cancer, the rate of […]

On the first day of a historic three-day meeting into cancer indications that were granted an accelerated approval by the Food and Drug Administration (FDA), the first one to come under discussion is staying in place, at least for now. Members of the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 7-2 in favor of keeping […]